Device Trial Radar · NCT04763018
Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users
Last checked: Nov 19, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
35
Planned (sponsor's estimate)
Start
Feb 17, 2021
Primary completion
May 1, 2021
Study completion Jun 1, 2021
Sponsor
- Lead sponsor
- Olympic Ophthalmics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two study arms - sham and treatment; There will be a cross over of the sham group to the treatment group at day 15.
Conditions
- Visual Display Users With Previously Undiagnosed Dry Eye
Interventions
iTEAR100Device
Neurostimulation external nasal nerve to stimulate tear production
Primary outcomes
What the sponsor says the trial is designed to measure.
- Meibomian Gland change in expressibilityTime frame: 14 days
- Corneal StainingTime frame: 14 days
- Basal tear outputTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fishman Vision
Palo Alto, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.